Patricia Horcajada1
IMDEA Energy Institute1
The involvement of Metal-Organic Frameworks (MOFs) in biomedical applications is currently one of the hot topics in the emerging field of hybrid porous solids.<sup>[1]</sup> Despite their already proven high loadings and progressive release of a wide variety of active ingredients (e.g. drugs, cosmetics, biological gases, macromolecules), the control of the biodistribution of MOF nanocarriers and their involvement as a non-passive carriers (bioactive) is still a challenge.<br/>Several examples of successful formulations able to bypass specific physiological barriers will be presented.<sup>[2]</sup> In particular, pulmonary administration is a convenient route not only for the treatment of respiratory diseases (e.g. COPD, asthma, tuberculosis, infection, cancer) but also systemic ones. In this sense, a pioneer combined anti-COVID multi-therapy (3-in-1 effect) will be described, paving the way to future treatment of challenging infectious and/or pulmonary pathologies.<sup>[3]</sup><br/><br/><br/><b>Acknowledgment: </b>The authors are grateful for the generous support from HeatNMof (H2020-MSCA-ITN-2019, ref. 860942), MOFSEIDON (PID2019-104228RB-I00 funded by MCIN/ AEI /10.13039/501100011033) and VIRMOF-CM (“Comunidad de Madrid” and European Regional Development Fund-FEDER 2014-2020-OE REACT-UE).<br/><br/><b>References</b><br/>[1] S. Rojas <i>et al., Coord. Chem. </i><i>Rev</i>., <b>2019</b>, 388, 202; R. Ettlinger <i>et al. Chem. Soc. Rev</i>., <b>2022</b>, 51, 464; S. Lelouche <i>et al. Expert Op. Drug Deliv</i>., <b>2022</b>, 19, 1417<br/>[2] T. Simon-Yarza <i>et al., Angew. Chem. Int. Ed.,</i> <b>2017</b>, 56(49), 15565; C. Fernandez-Paz <i>et al. ACS App. Mater. Inter.,</i> <b>2020</b>, 12(23), 25676; S.D. Taherzade <i>et al, Nanomater</i>. <b>2020</b>, 10, 2296; A. Botet-Carreras <i>et al. J Mater Chem B</i>, <b>2021</b>, 9, 2233; S. Rojas <i>et al. ACS Nano</i>. <b>2022</b>, 16, 4, 5830.<br/>[3] T. Hidalgo <i>et al.,</i> <i>Chem. Sci</i>., <b>2022</b>, 13, 934; A. Arenas-Vivo <i>et al. Pharmaceutics</i> <b>2023</b>, 15(1), 301; B. Fodor <i>et al.</i> unpublished results